Table 1.
Patients’ distribution based on treatment options along with adverse drug reactions
| L-AMB (ADR: n; percentage) | MILTE (ADR: n; percentage) | PARO (ADR: n; percentage) | L-AMB & MILTE (ADR: n; percentage) | L-AMB & PARO (ADR: n; percentage) | MILTE &PARO (ADR: n; percentage) | Total (ADR: n; percentage) | |
|---|---|---|---|---|---|---|---|
| NKA | 585 (179; 31%) | 12 (2; 2/17) | 0 (0; 0) | 1 (0; 0) | 9 (0; 0) | 1 (0; 0) | 608 (181; 30%) |
| PKDL | 155 (41; 26%) | 181 (29; 16%) | 0 (0; 0) | 15 (3; 3/15) | 0 (0; 0) | 0 (0; 0) | 351 (73; 21%) |
| RELAPSE VL | 64 (17; 27%) | 0 (0; 0) | 1 (0; 0) | 7 (0; 0) | 21 (0; 0) | 0 (0; 0) | 93 (17; 18%) |
| KATF | 3 (2; 2/3) | 0 (0; 0) | 0 (0; 0) | 1 (0; 0) | 0 (0; 0) | 0 (0; 0) | 4 (2; 2/4) |
| RELAPSE AND PKDL | 5 (2; 2/5) | 0 (0; 0) | 0 (0; 0) | 0 (0; 0) | 0 (0; 0) | 0 (0; 0) | 5 (2; 2/5) |
| CL | 2 (1; 1/2) | 0 (0; 0) | 0 (0; 0) | 0 (0; 0) | 0 (0; 0) | 0 (0; 0) | 2 (1; 1/2) |
| NKA WITH PKDL | 3 (0; 0) | 0 (0; 0) | 0 (0; 0) | 0 (0; 0) | 0 (0; 0) | 0 (0; 0) | 3 (0; 0) |
| Total (ADR: n; percentage) | 817 (242; 30%) | 193 (31; 16%) | 1 (0; 0) | 24 (3; 13%) | 30 (0; 0) | 1 (0; 0) | 1066 (276; 26%)a |
Note:
ADR adverse drug reactions, CL cutaneous leishmaniasis, KATF Kala-azar treatment failure, L-AMB liposomal amphotericin B, MILTE miltefosine, NKA New Kala-azar, PARO paromomycin, PKDL Post Kala-azar dermal leishmaniasis, VL visceral leishmaniasis
aWhere the percentage value has been calculated from the total number of ADRs, irrespective of disease type and treatment method